157 related articles for article (PubMed ID: 1377097)
1. Treatment of the carcinoid syndrome with somatostatin, salmon calcitonin, or octreotide.
Antonelli A; Gambuzza C; Bertoni F; Baschieri L
Clin Ther; 1992; 14(2):178-84. PubMed ID: 1377097
[TBL] [Abstract][Full Text] [Related]
2. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
3. [A prolonged-action somatostatin analog and carcinoid syndrome].
Chayvialle JA
Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
[TBL] [Abstract][Full Text] [Related]
4. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
5. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin analogue phase I trials in neuroendocrine neoplasms.
Anthony L; Johnson D; Hande K; Shaff M; Winn S; Krozely M; Oates J
Acta Oncol; 1993; 32(2):217-23. PubMed ID: 7686764
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of carcinoid syndrome with a somatostatin analogue].
Döbrönte Z; Stöckert A; Végh G; Varga L
Orv Hetil; 1992 Mar; 133(12):731-4. PubMed ID: 1372969
[TBL] [Abstract][Full Text] [Related]
8. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
O'Toole D; Ducreux M; Bommelaer G; Wemeau JL; Bouché O; Catus F; Blumberg J; Ruszniewski P
Cancer; 2000 Feb; 88(4):770-6. PubMed ID: 10679645
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of carcinoid syndrome with ocreotide (SMS-201-995)].
Rodríguez-García JL; Arechaga S; Fraile G; Serrano M
Rev Clin Esp; 1992 Jul; 191(3):168. PubMed ID: 1380173
[No Abstract] [Full Text] [Related]
10. [Effect of somatostatin and salmon calcitonin on carcinoid syndrome. A clinical case].
Festa V; Garrone C; Vietti Ramus G; Lisa F; Simone P; Scotti M; Cocchis D; Garrone GC
Minerva Chir; 1989 May; 44(9):1429-33. PubMed ID: 2569698
[TBL] [Abstract][Full Text] [Related]
11. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
Kulke MH; O'Dorisio T; Phan A; Bergsland E; Law L; Banks P; Freiman J; Frazier K; Jackson J; Yao JC; Kvols L; Lapuerta P; Zambrowicz B; Fleming D; Sands A
Endocr Relat Cancer; 2014 Oct; 21(5):705-14. PubMed ID: 25012985
[TBL] [Abstract][Full Text] [Related]
12. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
[TBL] [Abstract][Full Text] [Related]
13. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
Kulke MH; Hörsch D; Caplin ME; Anthony LB; Bergsland E; Öberg K; Welin S; Warner RR; Lombard-Bohas C; Kunz PL; Grande E; Valle JW; Fleming D; Lapuerta P; Banks P; Jackson S; Zambrowicz B; Sands AT; Pavel M
J Clin Oncol; 2017 Jan; 35(1):14-23. PubMed ID: 27918724
[TBL] [Abstract][Full Text] [Related]
14. Effects of somatostatin infusion in four patients with malignant carcinoid syndrome.
Quatrini M; Basilisco G; Conte D; Bozzani A; Bardella MT; Bianchi PA
Am J Gastroenterol; 1983 Mar; 78(3):149-51. PubMed ID: 6187212
[TBL] [Abstract][Full Text] [Related]
15. Effect of salmon calcitonin on symptoms and urinary excretion of 5 hydroxyindoleacetic acid in the carcinoid syndrome.
Antonelli A; Del Guerra P; Fierabracci A; Gori E; Baschieri L
Br Med J (Clin Res Ed); 1987 Oct; 295(6604):961. PubMed ID: 2445410
[No Abstract] [Full Text] [Related]
16. [Treatment with octreotide (SMS 201-995) in a case of intestinal carcinoid tumor].
Goñi F; Oleaga A; Goñi MJ; Monreal M; Yoldi A; González A; Llorente I; Moncada E
Rev Clin Esp; 1991 Nov; 189(7):331-4. PubMed ID: 1722585
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues.
Gut P; Ruchała M
Neuro Endocrinol Lett; 2019 Dec; 40(7-8):315-318. PubMed ID: 32304367
[TBL] [Abstract][Full Text] [Related]
18. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
[TBL] [Abstract][Full Text] [Related]
19. SMS 201-995 and provocation tests in preparation of patients with carcinoids for surgery or hepatic arterial embolization.
Ahlman H; Ahlund L; Dahlström A; Martner J; Stenqvist O; Tylén U
Anesth Analg; 1988 Dec; 67(12):1142-8. PubMed ID: 2461665
[TBL] [Abstract][Full Text] [Related]
20. [Symptomatic treatment of the malignant carcinoid syndrome with octreotide].
Alberts AS; Falkson G
S Afr Med J; 1989 Jan; 75(1):30-1. PubMed ID: 2911781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
